EACS2023: 908 Changes in inflammation biomarkers after switching to TAF/FTC/BIC in experienced, virally suppressed People Living with HIV (PLHIV). Real world data V. Petrakis , M. Panopoulou , P. Rafailidis , I. Terzi , P. Ouzounakis , D. Papazoglou , P. Panagopoulos Democritus University of Thrace, Department of Infectious Diseases, 2nd University Department of Internal Medicine, University General Hospital Alexandroupolis, Alexandroupolis, Greece, University Laboratory of Microbiology, University General Hospital Alexandroupolis, Alexandroupolis, Greece General data Abstract category: Antiretroviral therapy – observational studies Abstract body Purpose: The Highly Active Antiretroviral Therapy (HAART) has managed to improve quality of life and increase life expectancy of People Living with HIV (PLHIV). Integrase inhibitors (INSTIs) have shown significant efficacy with high in vitro genetic barrier to resistance. Recently approved Bictegravir (BIC) combined with Tenofovir Alafenamide Fumarate (TAF) and Emtricitabine (FTC) in a single-tablet treatment regimen has been proven efficient and safe. The aim of the present study is to evaluate the effect of TAF/FTC/BIC on chronic inflammation associated with HIV infection. Method: This is a prospective, observational study conducted in the Department of Infectious Diseases in University General Hospital of Alexandroupolis (Greece) including 64 virally suppressed PLHIV after switching treatment to TAF/FTC/BIC. Demographic, clinical and HIV-specific data, haematology and biochemistry tests, CD4+ and CD8+ T cell counts, CD4+/CD8+ ratio, sCD14, hsCRP, D-dimers, β2M, IL-6 and TNF-α levels were evaluated at baseline, at first, third, sixth month and twelfth month. The Kruskal-Wallis test and the Friedman test was used to compare changes in quantitative and continuous variables and correlations were assessed by Spearman's correlation coefficient. Results: The majority of patients were male (71%) and the median age was 45.0 years (IQR 38.0-66.8 years). The most frequent reason for switch was the reduction of drug-drug interactions (82%). The median increase in CD4+/CD8+ ratio was 0.22 (IQR 0.11-0.32), 0.12 (IQR 0.07-0.16) and 0.08 (IQR 0.06-0.12) at third, sixth and twelfth month respectively. The sCD14, IL-6, β2M, hsCRP, D-dimers and TNF-α levels showed significant decrease at 12 months after switching. Conclusions: The results of the present study indicate that TAF/FTC/BIC is an effective treatment option which maintains the viral suppression and reduces the levels of inflammation biomarkers. It is vital to include chronic inflammation in treatment strategy while it increases the risk of non-AIDS defining conditions such as cardiovascular disease, malignancies and neurological disorders. General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.). : Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 1 2 1 1 1 1 1 1 2 171
RkJQdWJsaXNoZXIy Mzc2ODc=